Impact of sarcopenia on outcomes of patients treated with trimodal therapy for muscle invasive bladder cancer

Almarzouq, Ahmad; Kool, Ronald; Bulushi, Yarab Al; Marcq, Gautier; Souhami, Luís; Cury, Fabio; Brimo, Fadi; Chong, Jaron; Kassouf, Wassim

doi:10.1016/j.urolonc.2021.11.002

Cited by 4 publications

(7 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, because bladder preservation therapy is less invasive compared with RC, bladder preservation therapy might be more preferable rather than RC in MIBC patients with sarcopenia. Similarly, in the study reported by Almarzouq et al, CR rates to trimodal therapy were comparable between sarcopenic and non-sarcopenic patients (39). Moreover, sarcopenia was not an independent predictor of OS.…”

Section: Discussionmentioning

confidence: 62%

“…Two papers reported responses to trimodal therapy and survival outcomes of bladder preservation therapy in MIBC patients with or without sarcopenia ( Table 2 ). Almarzouq et al showed the oncological outcomes of trimodal therapy, including TURB, chemotherapy [cisplatin alone (weekly at a dose of 40 mg/m 2 ), or gemcitabine alone (weekly at a dose of 100 mg/m 2 )], and radiotherapy (total dose: 44–66 Gy), using a cohort of 141 MIBC patients ( 39 ). They defined sarcopenia using the two definitions: the International and Martin’s definitions.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Impact of sarcopenia in bladder preservation therapy for muscle-invasive bladder cancer patients: a narrative review

Fukushima¹,

Koga²

2022

Transl Androl Urol

View full text Add to dashboard Cite

Background and Objectives: Muscle-invasive bladder cancer (MIBC) is a biologically aggressive disease and its prognosis is poor. Radical cystectomy (RC) with urinary diversion and lymph node dissection is the gold standard treatment for MIBC patients. Accumulating evidence indicates that sarcopenia, the degenerative and systemic loss of skeletal muscle mass, is a significant predictor of higher rates of mortality and perioperative complications following RC. Recently, bladder preservation therapy has been offered as an alternative in appropriately selected MIBC patients who desire to preserve their bladders and those unfit or unwilling for RC. Here, we performed a narrative review on the impact of sarcopenia on oncological outcomes and complication rates in MIBC patients treated with bladder preservation therapy.Methods: A literature review was performed using the PubMed and Scopus databases.

show abstract

Section: Discussionmentioning

confidence: 62%

Section: Methodsmentioning

confidence: 99%

Impact of sarcopenia in bladder preservation therapy for muscle-invasive bladder cancer patients: a narrative review

Fukushima¹,

Koga²

2022

Transl Androl Urol

View full text Add to dashboard Cite

show abstract

“…A total of 126 records were identified from databases and 27 duplicated records were removed. Eventually, nine studies were included [19][20][21][22][23][24][25][26][27]. The detailed selection process was shown in the Fig 1.…”

Section: Literature Searchmentioning

confidence: 99%

“…Among nine retrospective included studies, 1476 patients were enrolled and the sample size ranged from 80 to 500 [19][20][21][22][23][24][25][26][27]. Among four of included studies the cutoff values of SMI, 55cm 2 /m 2 for male and 39cm 2 /m 2 for female, were applied [19,21,24,27].…”

Section: Basic Characteristics Of Included Studiesmentioning

confidence: 99%

Predictive role of pretreatment skeletal muscle mass index for long-term survival of bladder cancer patients: A meta-analysis

Yuan

Feng

et al. 2023

PLoS ONE

View full text Add to dashboard Cite

Purpose To identify the predictive role of pretreatment skeletal muscle mass index (SMI) for long-term survival of bladder cancer patients. Methods Several databases were searched for studies investigating the relationship between pretreatment SMI and prognosis in bladder cancer. The overall survival (OS) and cancer-specific survival (CSS) were defined as primary and secondary outcomes, respectively. Hazard ratios (HRs) and 95% confidence intervals (CIs) were combined. Results Nine studies involving 1476 cases were included. The results demonstrated that a lower pretreatment SMI was significantly related to poorer OS (HR = 1.56, 95% CI: 1.33–1.82, P<0.001) and subgroup analysis based on thresholds of SMI revealed similar results. Besides, pretreatment SMI was also obviously related to CSS (HR = 1.75, 95% CI: 1.36–2.25, P<0.001). Conclusion Lower pretreatment SMI was associated with worse long-term survival of bladder cancer patients.

show abstract

“…Sarcopenic skeletal muscles are known to be insulin resistant even in the setting of low whole-body fat stores [ 70 ], and considering that skeletal muscle is a primary site of both insulin action and glucose uptake/storage [ 71–75 ], sarcopenia contributes significantly to systemic metabolic syndrome [ 76 ]. Numerous studies have shown detrimental epidemiological consequences of sarcopenic obesity on cancer incidence, progression, and survival, with the largest influence on cancer incidence [ 53 , 54 , 69 , 77–81 ]. Likely mechanisms of sarcopenia-associated insulin resistance include reduced mitochondrial function (i.e.…”

Section: Obesity's Link To Insulin Resistance and Hyperinsulinemiamentioning

confidence: 99%

Insulin and cancer: a tangled web

Leitner

Siebel

Akingbesote

et al. 2022

Biochemical Journal

View full text Add to dashboard Cite

For a century, since the pioneering work of Otto Warburg, the interwoven relationship between metabolism and cancer has been appreciated. More recently, with obesity rates rising in the U.S. and worldwide, epidemiologic evidence has supported a link between obesity and cancer. A substantial body of work seeks to mechanistically unpack the association between obesity, altered metabolism, and cancer. Without question, these relationships are multifactorial and cannot be distilled to a single obesity- and metabolism-altering hormone, substrate, or factor. However, it is important to understand the hormone-specific associations between metabolism and cancer. Here, we review the links between obesity, metabolic dysregulation, insulin, and cancer, with an emphasis on current investigational metabolic adjuncts to standard-of-care cancer treatment.

show abstract

Impact of sarcopenia on outcomes of patients treated with trimodal therapy for muscle invasive bladder cancer

Cited by 4 publications

References 25 publications

Impact of sarcopenia in bladder preservation therapy for muscle-invasive bladder cancer patients: a narrative review

Impact of sarcopenia in bladder preservation therapy for muscle-invasive bladder cancer patients: a narrative review

Predictive role of pretreatment skeletal muscle mass index for long-term survival of bladder cancer patients: A meta-analysis

Insulin and cancer: a tangled web

Contact Info

Product

Resources

About